Ignite Creation Date:
2024-05-06 @ 3:14 PM
Last Modification Date:
2024-10-26 @ 1:46 PM
Study NCT ID:
NCT04569032
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-18
First Post:
2020-09-23
Brief Title:
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10 CD30 Expression
Sponsor:
Seagen Inc
Organization:
Seagen Inc
Study Overview
Official Title:
A Dual-cohort Open-label Phase 2 Study of Brentuximab Vedotin and CHP ACHP in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma PTCL With Less Than 10 CD30 Expression
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma PTCL It will also find out what side effects occur when brentuximab vedotin and CHP are used together A side effect is anything the drugs do besides treating cancer CHP is a type of chemotherapy that uses three drugs cyclophosphamide doxorubicin and prednisone CHP is approved by the FDA to treat certain types of PTCL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None